Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
1.200
-0.010 (-0.83%)
At close: Nov 4, 2024, 4:00 PM
1.210
+0.010 (0.83%)
Pre-market: Nov 5, 2024, 8:20 AM EST
CNTB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 13.85 | 14.52 | 20.81 | 19.01 | 47.72 | 9.71 | |
| Research & Development | 38.59 | 51.91 | 96.63 | 80.5 | 150.93 | 106.41 | |
| Other Operating Expenses | -2.68 | -1.48 | -1.08 | -1.85 | -6.99 | -2.84 | |
| Operating Expenses | 49.75 | 64.95 | 116.36 | 97.66 | 191.66 | 113.29 | |
| Operating Income | -25.64 | -64.95 | -116.36 | -97.66 | -191.66 | -113.29 | |
| Interest Expense | -0.02 | -0.02 | -0.02 | -0.01 | -2.89 | -0.05 | |
| Interest & Investment Income | 5.2 | 5.22 | 1.81 | 0.17 | 1.39 | 1.86 | |
| Currency Exchange Gain (Loss) | 0.05 | 0.37 | 1.47 | -0.52 | -6.77 | 2.25 | |
| Other Non Operating Income (Expenses) | - | - | - | -103.98 | -579.29 | -59.4 | |
| EBT Excluding Unusual Items | -20.41 | -59.38 | -113.1 | -202 | -779.23 | -168.63 | |
| Asset Writedown | - | - | -4.7 | - | - | - | |
| Pretax Income | -21.26 | -59.38 | -117.79 | -202 | -779.23 | -168.63 | |
| Income Tax Expense | 0.12 | 0.12 | 0.3 | 0.27 | - | - | |
| Earnings From Continuing Operations | -21.38 | -59.5 | -118.09 | -202.27 | -779.23 | -168.63 | |
| Net Income | -21.38 | -59.5 | -118.09 | -202.27 | -779.23 | -168.63 | |
| Net Income to Common | -21.38 | -59.5 | -118.09 | -202.27 | -779.23 | -168.63 | |
| Shares Outstanding (Basic) | 55 | 55 | 55 | 52 | 17 | 17 | |
| Shares Outstanding (Diluted) | 55 | 55 | 55 | 52 | 17 | 17 | |
| Shares Change (YoY) | 0.14% | 0.04% | 5.49% | 205.31% | 1.27% | 36.71% | |
| EPS (Basic) | -0.39 | -1.08 | -2.15 | -3.88 | -45.60 | -9.99 | |
| EPS (Diluted) | -0.39 | -1.08 | -2.15 | -3.88 | -45.60 | -9.99 | |
| Free Cash Flow | -25.19 | -48.22 | -105.93 | -88.16 | -182.12 | -91.33 | |
| Free Cash Flow Per Share | -0.46 | -0.88 | -1.92 | -1.69 | -10.66 | -5.41 | |
| EBITDA | -24.95 | -64.23 | -115.63 | -97.17 | -190.7 | -112.91 | |
| D&A For EBITDA | 0.69 | 0.72 | 0.73 | 0.49 | 0.96 | 0.38 | |
| EBIT | -25.64 | -64.95 | -116.36 | -97.66 | -191.66 | -113.29 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.